PL370459A1 - Retynoidowi agoniści II typu podstawionego mocznika - Google Patents

Retynoidowi agoniści II typu podstawionego mocznika

Info

Publication number
PL370459A1
PL370459A1 PL02370459A PL37045902A PL370459A1 PL 370459 A1 PL370459 A1 PL 370459A1 PL 02370459 A PL02370459 A PL 02370459A PL 37045902 A PL37045902 A PL 37045902A PL 370459 A1 PL370459 A1 PL 370459A1
Authority
PL
Poland
Prior art keywords
substituted urea
cancer
emphysema
retinoid agonists
dermatological disorders
Prior art date
Application number
PL02370459A
Other languages
English (en)
Other versions
PL209697B1 (pl
Inventor
Michael Klaus
Jean-Marc Lapierre
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL370459A1 publication Critical patent/PL370459A1/pl
Publication of PL209697B1 publication Critical patent/PL209697B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL370459A 2001-09-18 2002-09-11 Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika PL209697B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32296201P 2001-09-18 2001-09-18

Publications (2)

Publication Number Publication Date
PL370459A1 true PL370459A1 (pl) 2005-05-30
PL209697B1 PL209697B1 (pl) 2011-10-31

Family

ID=23257206

Family Applications (1)

Application Number Title Priority Date Filing Date
PL370459A PL209697B1 (pl) 2001-09-18 2002-09-11 Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika

Country Status (16)

Country Link
US (1) US6838472B2 (pl)
EP (1) EP1430023B1 (pl)
JP (1) JP4410562B2 (pl)
KR (1) KR100891224B1 (pl)
CN (1) CN1301968C (pl)
AR (1) AR036532A1 (pl)
AT (1) ATE427929T1 (pl)
AU (1) AU2002340886B2 (pl)
BR (1) BR0212607A (pl)
CA (1) CA2458266C (pl)
DE (1) DE60231888D1 (pl)
ES (1) ES2325063T3 (pl)
MX (1) MXPA04002305A (pl)
PL (1) PL209697B1 (pl)
RU (1) RU2303027C2 (pl)
WO (1) WO2003024920A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1889830A1 (en) 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
EP1889837A1 (en) 2006-07-10 2008-02-20 Pharmeste S.r.l. VR1 vanilloid receptor antagonists with a iononic substructure
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
MX362239B (es) 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.
IL295440A (en) 2016-06-08 2022-10-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
EA039050B1 (ru) 2016-11-16 2021-11-26 Клементиа Фармасьютикалс Инк. Способы лечения множественного остеохондроматоза (мо)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87821A1 (fr) 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials

Also Published As

Publication number Publication date
EP1430023A1 (en) 2004-06-23
AU2002340886B2 (en) 2008-01-31
ES2325063T3 (es) 2009-08-25
ATE427929T1 (de) 2009-04-15
DE60231888D1 (de) 2009-05-20
CN1301968C (zh) 2007-02-28
PL209697B1 (pl) 2011-10-31
KR100891224B1 (ko) 2009-04-01
US20030125383A1 (en) 2003-07-03
BR0212607A (pt) 2004-08-17
AR036532A1 (es) 2004-09-15
CN1555357A (zh) 2004-12-15
WO2003024920A1 (en) 2003-03-27
CA2458266C (en) 2011-03-15
JP4410562B2 (ja) 2010-02-03
JP2005503411A (ja) 2005-02-03
RU2303027C2 (ru) 2007-07-20
CA2458266A1 (en) 2003-03-27
US6838472B2 (en) 2005-01-04
MXPA04002305A (es) 2004-06-29
RU2004111789A (ru) 2005-10-20
KR20040035808A (ko) 2004-04-29
EP1430023B1 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
CA2449729A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
JO2434B1 (en) New retinoids to treat emphysema
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
WO2004043341A3 (en) Treatment for hemorrhagic shock
MXPA03010761A (es) Combinaciones farmaceuticas.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PL370361A1 (pl) Retynoidowi agoniści I typu alkilomocznika
IL168308A (en) Compositions containing roflumilast and formoterol
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
PL370459A1 (pl) Retynoidowi agoniści II typu podstawionego mocznika
WO2003020213A3 (en) Methods and compositions for treating inflammatory disorders
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20120911